Clinical trials
Immune Checkpoint Therapy clinical trials
Below are recruiting immune checkpoint therapy clinical trials, each written for real people, not researchers. We’re tracking 153 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04615988Recruiting
Vitamin D levels and hormone side effects from immune cancer therapy
This study looks at whether your blood vitamin D level is linked to hormone-related side effects caused by immune checkpoint cancer drugs. It may help doctors better predict who is at risk and how to monitor patients during treatment.
New York, New YorkAges 18 years+ - NCT04624399RecruitingPhase 2
Atezolizumab before bladder or kidney-tract surgery
This trial tests atezolizumab (an immune therapy) given before surgery for certain bladder or upper urinary tract cancers. The goal is to shrink or control the cancer early and improve outcomes after curative surgery.
LondonAges 18–99 - NCT04751396Recruiting
Melanoma education for people with autoimmune conditions
This trial tests an educational tool to help people with melanoma and pre-existing autoimmune disease understand immune checkpoint inhibitor treatment. It aims to support you and your care team with information that can help you make decisions and feel more prepared.
Houston, TexasAges 18 years+ - NCT04913311Recruiting
Testing markers to predict lung inflammation after lung cancer treatment
This study looks for early “predictive markers” to tell who is most likely to develop lung inflammation after standard treatment for non-small cell lung cancer. It may help clinicians spot problems sooner and tailor care, using additional monitoring during treatment.
Houston, TexasAges Any age - NCT04954599RecruitingPhase 1/Phase 2
CP-506 for hard-to-treat cancers with DNA repair defects
This Phase 1/2 study tests CP-506 in people with advanced solid tumors that have specific DNA repair problems (homologous recombination or Fanconi anemia-related defects). It may be used alone or combined with carboplatin or an immune therapy, aiming to shrink tumors or improve control when standard options are limited.
BrusselsAges 18 years+ - NCT04977791Recruiting
Study how drug resistance develops in lung cancer immunotherapy
This study looks at lung tumor tissue and blood to understand why immune checkpoint drugs can stop working in non-small cell lung cancer. It may help researchers find better ways to predict and overcome drug resistance.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05010681RecruitingPhase 2
Lenvatinib plus immunotherapy after prior liver cancer treatment
This Phase 2 trial tests lenvatinib combined with the immunotherapy drug sintilimab in people with advanced liver cancer who got worse after prior PD-1/PD-L1 treatment. It aims to slow cancer growth and improve outcomes after immune therapy hasn’t worked.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05284539RecruitingPhase 2
Chemo plus immunotherapy for mutated advanced lung cancer
This trial studies whether combining platinum chemotherapy with immune “checkpoint” medicine works better for people with stage IV lung cancer that has EGFR, ALK, or ROS1 mutations. It focuses on tumors that have grown again after first-line treatment.
Changsha, HunanAges 18 years+ - NCT05335928RecruitingPhase 3
Abatacept for immune-therapy heart inflammation in hospitalized adults
This Phase 3 trial tests abatacept to treat myocarditis (inflammation of the heart muscle) caused by immune checkpoint cancer medicines. It may help patients recover faster and safely manage this serious side effect while they are in the hospital.
Los Angeles, CaliforniaAges 18 years+ - NCT05430009RecruitingPhase 1
Radiation to liver plus immunotherapy for metastatic lung cancer
This Phase 1 study tests whether targeted radiation to liver tumors combined with immunotherapy can control metastatic non-small cell lung cancer. It aims to find a safe and effective treatment approach for people whose cancer has spread to the liver.
Ann Arbor, MichiganAges 18 years+ - NCT05502913RecruitingPhase 2
Fecal transplant plus cancer immunotherapy for lung cancer
This trial studies whether giving a fecal microbiota transplant (a stool-based sample from a carefully screened donor) alongside immune checkpoint inhibitors can improve outcomes in people with lung cancer. It aims to change the gut bacteria to help the immune system work better against the cancer.
BeershebaAges 18 years+ - NCT05754203Recruiting
Radiation plus immunotherapy for advanced lung cancer
This trial studies whether a more intensive form of targeted radiation, combined with immunotherapy (immune checkpoint inhibitors), can work better and be safe for people with advanced non-small cell lung cancer. You may be considered if your tumor is limited in size and you’re able to receive both treatments.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT05810402Recruiting
Testing immunotherapy for advanced liver cancer using blood tests
This study looks at how well immune-checkpoint therapy (a PD-1 or PD-L1 immunotherapy) works for advanced liver cancer, using “liquid biopsy” blood testing to guide or monitor care. It may help your team better track your cancer and response without needing repeated tissue biopsies.
MontpellierAges 18 years+ - NCT05947669RecruitingPhase 3
Infliximab for diarrhea or colitis from immune cancer therapy
This trial studies whether infliximab can treat stomach inflammation in the colon (colitis) or frequent diarrhea caused by immune checkpoint cancer drugs. It aims to improve symptoms safely for adults with certain solid cancers.
AalborgAges 18 years+ - NCT05973344Recruiting
Study of side effects from immunotherapy in cancer care
This study looks at how people’s bodies respond to cancer immunotherapy and why some people get side effects. Your information and lab results may help improve how immunotherapy is managed in the future.
BrestAges 18 years+ - NCT06107608Recruiting
Scan for tumors in lung cancer patients on immunotherapy
This study uses a special type of PET scan to look at specific cells in non-small cell lung cancer tumors that might help doctors understand how well immunotherapy treatments are working. If you are about to start immunotherapy for advanced lung cancer, you may be able to join.
BrusselsAges 18 years+ - NCT06168032Recruiting
COVID-19 vaccine for lung cancer patients
This trial is testing how well the COVID-19 vaccine works for people with lung cancer to prevent another infection. It also looks at certain biomarkers in your blood that might help predict your body's immune response.
BeijingAges 18 years+ - NCT06199713Recruiting
Melanoma trial tracking treatment response with PET scans and blood tests
This study is looking at whether a special PET scan (FDG PET/CT) and a blood test that measures ctDNA (cancer DNA in the blood) can help predict how well immune checkpoint inhibitors work in people with advanced melanoma. If you are planning to get treatment with immunotherapy drugs like ipilimumab, nivolumab, or pembrolizumab, you may be able to join.
Madison, WisconsinAges 18 years+ - NCT06255223RecruitingPhase 2
Radiation therapy plus immunotherapy for advanced kidney cancer
This trial tests a combination of targeted radiation therapy with a restart of immunotherapy for people whose kidney cancer has grown after prior immunotherapy. It aims to see if radiation can help the immune system fight the cancer again.
Nanjing, JiangsuAges 18–80 - NCT06346197RecruitingPhase 3
Immunotherapy combo for advanced MSI-H stomach/esophageal cancer
This trial tests a combination of immune checkpoint inhibitors (nivolumab, botensilimab, and balstilimab) plus chemotherapy for people with advanced stomach or esophageal cancer that has a specific genetic instability (MSI-H/dMMR) and expresses PD-L1. It may be an option for those who haven't had prior immunotherapy or chemotherapy for advanced disease.
BrestAges 18 years+ - NCT06349642Recruiting
Testing a live tumor test for immune therapy response
This trial uses a special test on live tumor samples to see if it can predict how well immune checkpoint inhibitors (a type of immunotherapy) will work for different cancers. It may help doctors choose the best treatment for you.
Phoenix, ArizonaAges 18 years+ - NCT06388031RecruitingPhase 2
Re-trying immunotherapy for advanced lung cancer after long-term success
This trial tests whether giving immunotherapy again can help people with advanced non-small cell lung cancer whose disease stayed stable for at least 2 years on their first immunotherapy but then started growing. It aims to see if a second course of treatment can work again.
BeijingAges 18–80 - NCT06422403RecruitingPhase 2
Study on giving immunotherapy less often for advanced cancer
This trial tests whether giving certain immunotherapy drugs less often than usual is safe and still works well for people with advanced stomach, liver, or lung cancer. It might mean fewer hospital visits while still controlling the cancer.
SingaporeAges 21–99 - NCT06472245RecruitingPhase 3
Cancer vaccine for lung cancer that stopped responding to immunotherapy
This trial tests a therapeutic cancer vaccine called OSE2101 for people with advanced non-small cell lung cancer whose tumors stopped responding to an immunotherapy drug. The vaccine is designed to help your immune system fight the cancer in a different way.
Beverly Hills, CaliforniaAges 18 years+
Hear when a new Immune Checkpoint Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immune checkpoint therapy?
- Yes. Clin2 currently lists 153 recruiting immune checkpoint therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immune checkpoint therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immune checkpoint therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.